Clinical & Industry News

“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.

The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.

Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...

The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.

The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.

In a statement, Drs. Martin Leon, Ajay Kirtane, William Fearon, and Allen Jeremias stated: "The compelling results should serve as the impetus to increase adoption of physiology worldwide."

At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...